<doc>
  <docmeta id="113hr5657ih">
    <bill congress="113" type="hr" number="5657" version="ih"/>
    <revision size="23787" annotations="0" status="complete" id="4" commit-time="2014-10-21T16:38:39Z" committer="mbohmer" doc="113hr5657ih/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H4B1AFAC38C9A497C81B2BC7DC458C557" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 5657 IH: FAST Generics Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-09-18</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 5657</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140918">September 18, 2014</action-date>
			<action-desc>
        <sponsor name-id="S001187">Mr. Stivers</sponsor> (for himself and <cosponsor name-id="W000800">Mr. Welch</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have
			 competitive access to approved drugs and licensed biological products, so
			 as to enable eligible product developers to develop and test new products,
			 and for other purposes.</official-title>
	</form>
	<legis-body id="HE7123CEC06004969AFF4D473E38237D9" style="OLC">
		<section commented="no" id="HFD47D1A12BAC427EA34726E0A8D58A42" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <quote>
          <short-title>
              <cato:entity-ref entity-type="act" value="Fair Access for Safe and Timely Generics Act of 2014" proposed="true">Fair Access for Safe and Timely Generics Act of 2014</cato:entity-ref>
            </short-title>
        </quote> or the <quote>
            <cato:entity-ref entity-type="act" value="FAST Generics Act of 2014" proposed="true">FAST Generics Act of 2014</cato:entity-ref>
          </quote>
        </cato:entity>.</text>
		</section>
    <section id="HC38DEC13BA844EF4AF61BEFE38C0E9BD">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">Congress finds the following:</text>
			<paragraph id="HFB43C92ED2D64F29B7F6B98B18B9C84E">
        <enum>(1)</enum>
        <text>Reference product license or approval holders are restricting competitive access to reference
			 products by sponsors seeking to develop drugs, generic drugs, and
			 biosimilars under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Food, Drug, and Cosmetic Act/s:505/ss:j">505(j) of the Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/b/2">21 U.S.C. 355(b)(2)</cato:entity-ref>
          </external-xref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/j">355(j)</cato:entity-ref>) and under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public
			 Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/262">
            <cato:entity-ref entity-type="uscode" value="usc/42/262">42 U.S.C. 262</cato:entity-ref>
          </external-xref>)</cato:entity>. These restrictions are deterring and
			 delaying development of generic drugs and biosimilars by extending lawful
			 patent-based monopolies beyond their lawful patent life.</text>
			</paragraph>
      <paragraph id="HBA23909267764747BC86D305FD2217AE">
        <enum>(2)</enum>
        <text>The enforcement provisions set forth in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1/ss:f/p:8">section 505–1(f)(8) of the Federal Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">
            <cato:entity-ref entity-type="uscode" value="usc/21/355–1/f/8">21 U.S.C. 355–1(f)(8)</cato:entity-ref>
            </external-xref>)</cato:entity> have not been sufficient to prevent
			 anti-competitive practices that interfere with access to reference
			 products which is necessary for the timely development of affordable
			 generic drugs and biosimilars.</text>
			</paragraph>
      <paragraph id="HAC67E70100BC4CA8A99508817F65002C">
        <enum>(3)</enum>
        <text>The opinion in Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398
			 (2004) should not be construed to impair or bar the application of the
			 antitrust
			 laws consistent with the provisions of this Act.</text>
			</paragraph>
      <paragraph id="H9EC77238385D441D86289E75BF4688BD">
        <enum>(4)</enum>
        <text>There is not a regulatory structure in place that is sufficient to deter or remedy the
			 anti-competitive harm that results when access to reference brand products
			 is restricted to sponsors developing drugs, generic drugs, and biosimilars
			 in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">505(j) of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/21/355/b/2">21 U.S.C. 355(b)(2)</cato:entity-ref>
          </external-xref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:355/ss:j">355(j)</cato:entity-ref>), and <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351">section 351 of the
			 Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/262">
            <cato:entity-ref entity-type="uscode" value="usc/42/262">42 U.S.C. 262</cato:entity-ref>
          </external-xref>)</cato:entity>, respectively.</text>
			</paragraph>
      <paragraph id="H06FF2EF313C3472D91F30B8EC8B9DB3C">
        <enum>(5)</enum>
        <text display-inline="yes-display-inline">Requiring license holders to comply with requirements for competitive access to their products, and
			 subjecting license holders to antitrust liability for failing to do so,
			 will not impose obligations on the courts that they cannot adequately and
			 reasonably adjudicate.<italic/>
        </text>
			</paragraph>
    </section>
    <section id="H4DC28075102142AAA1E62B5CCDEA8009">
      <enum>3.</enum>
      <header>Competitive access to covered products for development purposes</header>
			<subsection id="HDE051360CFC2494EA778953E4AECE5FC">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Food Drug and Cosmetic Act/ch:V">Chapter V of the Food Drug and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
            <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq.</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by inserting after
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Food Drug and Cosmetic Act/s:505–1">section 505–1 of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">
            <cato:entity-ref entity-type="uscode" value="usc/21/355–1">21 U.S.C. 355–1</cato:entity-ref>
            </external-xref>)</cato:entity> the following new section:</text>
				<quoted-block display-inline="no-display-inline" id="H0916A6E1349E42D997A3D972F3E0DF9E" style="OLC">
					<section id="H379EA604454049F18AD2EE90DBC778BD">
            <enum>505–2.</enum>
            <header>Competitive access to covered products for development purposes</header>
						<subsection id="H285B5A7F594B45259729B29A12669895">
              <enum>(a)</enum>
              <header>Definitions</header>
              <text display-inline="yes-display-inline">In this section:</text>
							<paragraph id="H609DAE322B594821B1D31D406066F0E2">
                <enum>(1)</enum>
                <header>Covered product</header>
                <text display-inline="yes-display-inline">The term <term>covered product</term> means any drug approved under section 505 or any biological product that is licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section
			 351 of the Public Health Service Act</cato:entity-ref>, including—</text>
								<subparagraph id="H22C6E76FA01742C6997268FC9830B801">
                  <enum>(A)</enum>
                  <text>any combination thereof; and</text>
								</subparagraph>
                <subparagraph id="HBC9391851992487E80D8C44E0D65DA57">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">when reasonably necessary to demonstrate sameness, biosimilarity, or interchangeability for
			 purposes of this section, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health
			 Service Act</cato:entity-ref> (as applicable), any product, including any device, that is
			 marketed or intended for use with such drug or biological product.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H16E0E40E05DC45489154386DF1DF5B30">
                <enum>(2)</enum>
                <header>Eligible product developer</header>
                <text display-inline="yes-display-inline">The term <term>eligible product developer</term> means a person that seeks to develop an application for the approval of a drug under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section
			 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">505(j)</cato:entity-ref> or the licensing of a biological product under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section
			 351 of the Public Health Service Act</cato:entity-ref>.</text>
							</paragraph>
              <paragraph commented="no" id="H357EE5BC7321453D883FED9761E79D39">
                <enum>(3)</enum>
                <header>License holder</header>
                <text display-inline="yes-display-inline">The term <term>license holder</term> means the holder of an application approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">section 505(j)</cato:entity-ref> or a license
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> for a covered product
			 (including the holder’s agents, wholesalers, distributors, assigns, and
			 corporate affiliates).</text>
							</paragraph>
              <paragraph id="H264AC1CB8F8242649B960D7DAFC430B6">
                <enum>(4)</enum>
                <header>REMS product</header>
                <text display-inline="yes-display-inline">The term <term>REMS product</term> means a covered product that—</text>
								<subparagraph id="H3218061F2B234CF483C0DA97EA8DB58C">
                  <enum>(A)</enum>
                  <text>is subject to a risk evaluation and mitigation strategy under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section 505–1</cato:entity-ref>; or</text>
								</subparagraph>
                <subparagraph id="H24792686979240CD947A670749600A5D">
                  <enum>(B)</enum>
                  <text>is deemed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Food and Drug Administration Amendments Act of 2007/s:909/ss:b">section 909(b) of the Food and Drug Administration Amendments Act of 2007</cato:entity-ref> to have
			 in effect an approved risk evaluation and mitigation strategy under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section 505–1</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" id="HCA12802BDF3E4628BF0194D3467E3129">
              <enum>(b)</enum>
              <header>Competitive access to covered products as a condition on approval or licensing</header>
              <text display-inline="yes-display-inline">As a condition of approval or licensure, or continuation or renewal of approval or licensure, of a
			 covered product under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:505">section 505 of this Act or section 351 of the Public
			 Health Service Act</cato:entity-ref>, respectively, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall require that the
			 covered product’s license holder not adopt, impose, or enforce any
			 condition relating to the sale, resale, or distribution of the covered
			 product, including any condition adopted, imposed, or enforced as an
			 aspect of a risk evaluation and mitigation strategy approved by the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that restricts or has the effect of restricting the supply of
			 such covered product to an eligible product developer for development or
			 testing purposes.</text>
						</subsection>
            <subsection id="H52CF29A3DEDA4997931A045944E875BE">
              <enum>(c)</enum>
              <header>Competitive access to covered products other than REMS products for development purposes</header>
              <text display-inline="yes-display-inline">No license holder shall adopt, impose, or enforce any condition relating to the sale, resale, or
			 distribution of a covered product that interferes with or restricts access
			 to reasonable quantities of a covered product by an eligible product
			 developer for development and testing purposes, at commercially
			 reasonable, market-based prices, from the license holder or from any
			 wholesaler or specialty distributor authorized by the license holder to
			 commercially distribute or sell the covered product <italic>
								</italic>unless the license holder generally adopts, imposes, or enforces lawful conditions relating to the
			 sale, resale, or distribution of a covered product, with respect to other
			 buyers of the covered product.</text>
						</subsection>
            <subsection id="HD2AE88927D4641DCACDA222C7BEF236D">
              <enum>(d)</enum>
              <header>Competitive access to REMS products for development purposes</header>
							<paragraph id="HC49AC1468ED84D219F9E0A897234AFB1">
                <enum>(1)</enum>
                <header>Prohibited use of REMS to restrict access</header>
                <text display-inline="yes-display-inline">With respect to a REMS product, no aspect of a risk evaluation and mitigation strategy under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section 505–1</cato:entity-ref> shall prohibit or restrict, or be construed or applied to
			 prohibit or restrict, the supply of such REMS product to an eligible
			 product developer for development and testing purposes, at commercially
			 reasonable, market-based prices, from the REMS product’s license holder or
			 from any wholesaler or specialty distributor authorized by the license
			 holder to commercially distribute or sell the REMS product.</text>
							</paragraph>
              <paragraph id="H06E97D15ACE745A3A60E12994D36738B">
                <enum>(2)</enum>
                <header>Single, shared system of elements to assure safe use</header>
                <text>With respect to a REMS product, no license holder shall take any step that impedes—</text>
								<subparagraph id="H424D1101343A48D383598DF095F372D3">
                  <enum>(A)</enum>
                  <text>the prompt development of a single, shared system of elements to assure safe use under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section
			 505–1</cato:entity-ref>; or</text>
								</subparagraph>
                <subparagraph id="HCAB7CEFE44954CDBB36071C68BFC3A55">
                  <enum>(B)</enum>
                  <text>the entry on commercially reasonable terms of an eligible product developer into a previously
			 approved system of elements to assure safe use.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HD6D3CECFA02E48ADAAE43AD6367AB85A">
              <enum>(e)</enum>
              <header>Procedures for obtaining access to covered products</header>
							<paragraph id="HEA3F9F79304141528E6666AF84CF7BF6">
                <enum>(1)</enum>
                <header>Competitive access</header>
                <text display-inline="yes-display-inline">Notwithstanding any other provision of law, in the case of an eligible product developer that has
			 an authorization to obtain a covered product in effect under paragraph (2)
			 or (3), no license holder shall adopt, impose, or enforce any other
			 condition relating to the sale, resale, or distribution of such covered
			 product that interferes with or restricts access to reasonable quantities
			 of the covered product by the eligible product developer for development
			 and testing purposes, at commercially reasonable, market-based prices,
			 from the license holder or from any wholesaler or specialty distributor
			 authorized by the license holder to commercially distribute or sell the
			 covered product, unless the license holder generally adopts, imposes, or
			 enforces lawful conditions relating to the sale, resale, or distribution
			 of a covered product, with respect to other buyers of the covered product.</text>
							</paragraph>
              <paragraph id="HA71B636A4D3A40AC888C44F9AAEFE915">
                <enum>(2)</enum>
                <header>General covered products authorization</header>
                <text>Any eligible product developer may seek a general covered products authorization, authorizing the
			 eligible product developer to obtain any covered product for the purposes
			 of development and testing, by making a written request to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.
			 Within 60 days after receiving such a request, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, by
			 written notice, issue such authorization if—</text>
								<subparagraph id="H9F5DA53093774D5D865005DC08CB647E">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">the eligible product developer holds one or more approved applications or licenses for a covered
			 product or, in the absence of such approvals or licensures, otherwise
			 establishes that the eligible product developer can comply with the
			 requirements of this Act and other applicable law for the development and
			 testing of covered products; and</text>
								</subparagraph>
                <subparagraph id="H2AF3EF6CB51744BABF2E5A81EFD6F6AF">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not find that the eligible product developer has materially failed to comply
			 with the requirements of this Act or other applicable law for the
			 development and testing of covered products.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H15ADFCE7503041BA8B05AD5703BA02B1">
                <enum>(3)</enum>
                <header>Individual covered product authorization</header>
                <text display-inline="yes-display-inline">Any eligible product developer may seek an authorization to obtain an individual covered product
			 for development and testing purposes by making a written request to the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. Within 60 days of receiving such a request, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 shall, by written notice, issue such authorization for purposes of—</text>
								<subparagraph id="H1FFF8D5706764A0EA4E90B7D0AD16C1C">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">development and testing that does not involve human clinical trials, if the eligible product
			 developer has agreed to comply with any conditions the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 determines necessary; or</text>
								</subparagraph>
                <subparagraph id="H14698E52FDCB42BEBF34182DACD2F862">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">testing that involves human clinical trials if the eligible product developer has submitted a
			 protocol for testing that includes protections that will provide an
			 assurance of safety comparable to the assurance of safety provided by any
			 distribution restrictions governing the approval or licensure of the
			 covered product or the license holder’s distribution of the covered
			 product.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H903E56EC69D546A7909E98DE27C4C8FC">
                <enum>(4)</enum>
                <header>Failure by Secretary to take final action</header>
                <text display-inline="yes-display-inline">If the 60-day period referred to in paragraph (2) or (3) expires without the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> having taken
			 final action on the request for authorization, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be
			 deemed to have issued, by written notice, the requested authorization.</text>
							</paragraph>
              <paragraph id="H9C13C818D2D44C4EB11C7A0677FBCFF4">
                <enum>(5)</enum>
								<subparagraph commented="no" display-inline="yes-display-inline" id="H90D85AD3E85C4583AE93FDFE67534F83">
                  <enum>(A)</enum>
                  <header>Process for obtaining product pursuant to an authorization</header>
                  <text display-inline="yes-display-inline">If an eligible product developer is unable, for purposes of development and testing, to obtain
			 reasonable quantities of a covered product commercially, either from the
			 license holder or from any wholesaler or specialty distributor authorized
			 by the license holder to commercially distribute or sell the covered
			 product, any eligible product developer that has obtained authorization to
			 do so, in accordance with paragraph (2) or (3), shall be entitled to
			 obtain such reasonable quantities of such covered product at the same
			 commercially reasonable, market based price on which such reasonable
			 quantities of such covered product have been previously sold by the
			 license holder to third parties in the open market. Such eligible product
			 developer shall initiate its acquisition of such covered product by
			 providing a written request for specific quantities of such covered
			 product either—</text>
									<clause id="H111B92FDE40041E488F2154205B207E7" indent="up1">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">to any wholesaler or specialty distributor authorized by the license holder to commercially
			 distribute or sell the covered product; or</text>
									</clause>
                  <clause id="H6DDB24F87A6E4110B3C774B50E0F0B3C" indent="up1">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">in the event no such wholesaler or specialty distributor has been designated for such purpose by
			 the license holder, to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HED604D1445AA46F88F6DFE0825806499" indent="up1">
                  <enum>(B)</enum>
                  <header>Request contents</header>
                  <text display-inline="yes-display-inline">Such request shall include a statement regarding the quantity of covered product sought for
			 development or testing purposes, and state that either—</text>
									<clause id="HD75BED155F324A6BBF25859A538B4FB9">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">the eligible product developer has, or is deemed to have, a general covered products authorization
			 under paragraph (2); or</text>
									</clause>
                  <clause id="HAB174570FD894B6CB77A18A0AE7E81F6">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">the eligible product developer has, or is deemed to have, an authorization under paragraph (3) to
			 obtain the specific covered product.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="H8C1383EA2BE64B7FB86AE115FD83740D" indent="up1">
                  <enum>(C)</enum>
                  <header>Disclosure of information by wholesalers and specialty distributors</header>
                  <text display-inline="yes-display-inline">In the event that a request is made to a wholesaler or specialty distributor under this paragraph,
			 the wholesaler or specialty distributor shall not disclose to the license
			 holder of the covered product involved the identity of the eligible
			 product developer, but may disclose to such license holder, only if
			 required to do so by the holder—</text>
									<clause commented="no" id="H71963706510D461285FE5EA19139BD3A">
                    <enum>(i)</enum>
                    <text>the fact that a request has been made;</text>
									</clause>
                  <clause commented="no" id="H08FEF2AFFF2E4915B6E2F7342C3011A1">
                    <enum>(ii)</enum>
                    <text>the dates on which the request was made and fulfilled;</text>
									</clause>
                  <clause commented="no" id="HA80D7B584FF54A88B898E6CCA151A547">
                    <enum>(iii)</enum>
                    <text>the commercial terms on which the request was fulfilled; and</text>
									</clause>
                  <clause commented="no" id="H866F4A142C70411D892EE5E2CC644286">
                    <enum>(iv)</enum>
                    <text>the quantity of the covered product furnished by the wholesaler or specialty distributor in
			 compliance with the request.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H3D6D727157E14E91979317883114964B" indent="up1">
                  <enum>(D)</enum>
                  <header>Disclosure pursuant to means specified by Secretary</header>
                  <text display-inline="yes-display-inline">In the event that a request is made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under this subsection, then the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 shall, within 5 business days of receipt of the request, notify the
			 license holder that a request for such covered product has been made, and
			 the quantity of the covered product requested, and such license holder
			 shall, within 30 days after receiving notice from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, provide
			 the quantity of the requested covered product, through means specified by
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, at a non-discriminatory, commercially reasonable,
			 market-based price for which such covered product has been previously sold
			 by the license holder (or any wholesaler or specialty distributor
			 authorized by the license holder to commercially distribute or sell the
			 covered product) to third parties in the open market. The means
			 established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under this clause shall not disclose to the
			 license holder the identity of the eligible product developer that has
			 requested quantities of the covered product for development and testing
			 purposes.</text>
								</subparagraph>
                <subparagraph id="H1A48BF1F49874596AC75D42E3644DA74" indent="up1">
                  <enum>(E)</enum>
                  <header>Imminent hazard</header>
                  <text display-inline="yes-display-inline">At any time, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may prohibit, limit, or otherwise suspend a transfer of a covered
			 product to an eligible product developer if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that
			 the transfer of such product to the eligible product developer would
			 present an imminent hazard to the public health. In such cases, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify the basis for the determination, including the
			 specific information available to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> which served as the basis
			 for such determination, and confirm such determination in writing.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection commented="no" id="HE02FC531ED2C4CE9A1948C53B5958A62">
              <enum>(f)</enum>
              <header>Public and private enforcement</header>
							<paragraph commented="no" id="H6491237105EE41DC9B3AC1CA370C139E">
                <enum>(1)</enum>
                <header>Application of certain provisions</header>
                <text>For purposes of this Act and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act">Public Health Service Act</cato:entity-ref>, a violation of a requirement or
			 prohibition in subsection (b), (c), (d)(1), (d)(2), or (e)(1) shall be
			 treated in the case of a REMS product, as a violation of the product’s
			 risk evaluation and mitigation strategy.</text>
							</paragraph>
              <paragraph id="H7A6F347A39C847D8B994BE03183BEBFB">
                <enum>(2)</enum>
                <header>Remedies</header>
                <text display-inline="yes-display-inline">An eligible product developer that has authorization for access to a covered product from the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under subsection (e) and that is aggrieved by a violation of
			 subsection (b), (c), (d)(1), (d)(2), or (e)(1) by a license holder or any
			 wholesaler or specialty distributor authorized by the license holder to
			 commercially distribute or sell the covered product may sue such license
			 holder for injunctive relief and treble damages (including costs and
			 interest of the kind described in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                    <cato:entity-ref entity-type="act" value="Clayton Act/s:4/ss:a">section 4(a) of the Clayton Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/15/15/a">15
			 U.S.C. 15(a)</cato:entity-ref>)</cato:entity>).</text>
							</paragraph>
            </subsection>
            <subsection id="HD1FBD96793624D6DAB25227D41EFE4AD">
              <enum>(g)</enum>
              <header>Limitation of liability</header>
              <text display-inline="yes-display-inline">The holder of an approved application or license for a covered product shall not be liable for any
			 claim arising out of an eligible product developer’s development or
			 testing activities conducted under this section, including a claim arising
			 out of a failure of the eligible drug developer to follow adequate
			 safeguards to assure safe use of the covered product.</text>
						</subsection>
            <subsection commented="no" id="H10EF251BA99F43AD92A8DCDA74BE8981">
              <enum>(h)</enum>
              <header>Reports</header>
							<paragraph commented="no" id="H9657337A107B44AF8ECB41293469C75C">
                <enum>(1)</enum>
                <header>Report by FDA</header>
                <text display-inline="yes-display-inline">Not later than 180 days after the enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair Access for Safe and Timely Generics Act of 2014" proposed="true">Fair Access for Safe and Timely Generics Act of 2014</cato:entity-ref>
                  </short-title>, and annually thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Commissioner of Food and Drugs</cato:entity-ref>, shall
			 submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> a report that—</text>
								<subparagraph id="H80714725630E4593A4DF6687FD0E982F">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">identifies each instance of noncompliance by any license holder with a requirement or prohibition
			 in subsection (b), (c), (d)(1), (d)(2), or (e)(1); and</text>
								</subparagraph>
                <subparagraph id="H808ACB0EC9684DBFBE1A20D595E26D3E">
                  <enum>(B)</enum>
                  <text>describes the actions taken by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to remedy such noncompliance and to enforce such
			 requirements and prohibitions, whether by assessment of a penalty or
			 otherwise.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="H0ED8C93608C94FA7B2A4A1FB4CE5DDF8">
                <enum>(2)</enum>
                <header>Report by FTC</header>
                <text display-inline="yes-display-inline">Not later than 270 days after the enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair Access for Safe and Timely Generics Act of 2014" proposed="true">
                    <short-title>Fair Access for Safe and Timely Generics Act of 2014</short-title>
                  </cato:entity-ref>, and annually thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="2900" entity-type="federal-body">Federal Trade Commission</cato:entity-ref> shall submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> a report that—</text>
								<subparagraph id="H1AF9C87D51EB44E083E675E49A5175BB">
                  <enum>(A)</enum>
                  <text>describes the complaints received by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> pertaining to the withholding of competitive
			 access to covered products, the actions taken by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref> with
			 respect to each such complaint, and the result of each such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="2900">Commission</cato:entity-ref>
			 action; and</text>
								</subparagraph>
                <subparagraph id="H5490C3F7145041279C93D6784F36FEFC">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">examines the impact on the market entry of competing drug products, and the pricing and
			 availability of such products, in the United States resulting from
			 noncompliance by license holders with a requirement or prohibition in
			 subsection (b), (c), (d)(1), (d)(2), or (e)(1).</text>
								</subparagraph>
              </paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection commented="no" id="H1A19F68E763049D8BF773CADF78399B2">
        <enum>(b)</enum>
        <header>Prohibited act</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301">Section 301 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
            <cato:entity-ref entity-type="uscode" value="usc/21/331">21 U.S.C. 331</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by adding at the
			 end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H557C72FD942E47ADB401F4663051E7BC" style="OLC">
					<subsection commented="no" id="H42311CD5CBCA444F93AC7C55339CEA6B">
            <enum>(ddd)</enum>
            <text display-inline="yes-display-inline">Any violation by the license holder of a covered product (as such terms are defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/ss:a" proposed="true">section
			 505–2(a)</cato:entity-ref> (including its contractors, assigns, or corporate affiliates)) of
			 a requirement or prohibition in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/ss:b" proposed="true">subsection (b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/ss:c" proposed="true">(c)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/sch:d/p:1" proposed="true">(d)(1)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/sch:d/p:2" proposed="true">(d)(2)</cato:entity-ref>, or
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/sch:e/p:1" proposed="true">(e)(1) of section 505–2</cato:entity-ref> (relative to competitive access to covered
			 products for development purposes).</text>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection commented="no" id="H32F63F5CF7EE429B8DABC253639876F7">
        <enum>(c)</enum>
        <header>Waiver of single, shared system requirement</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1/ss:i/p:1/sp:B">Section 505–1(i)(1)(B) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">
            <cato:entity-ref entity-type="uscode" value="usc/21/355–1/i/1/B">21 U.S.C. 355–1(i)(1)(B)</cato:entity-ref>
            </external-xref>)</cato:entity> is
			 amended—</text>
				<paragraph id="H987A17A6F4C34E09BCD332B8B8B9BC08">
          <enum>(1)</enum>
          <text>in clause (i), by striking <quote>or</quote> at the end;</text>
				</paragraph>
        <paragraph id="HF1319E1732714A3E8F76860759BE8A30">
          <enum>(2)</enum>
          <text>in clause (ii), by striking the period at the end and inserting <quote>; or</quote>; and</text>
				</paragraph>
        <paragraph id="HC5F21EE3746C44478EBBA98C046530E7">
          <enum>(3)</enum>
          <text>by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="HC9E92FAD776148DD9852D04DAEF89384" style="OLC">
						<clause commented="no" id="HE4AFFB20DE53422DBFD43D33B4A1BCB2">
              <enum>(iii)</enum>
              <text display-inline="yes-display-inline">the applicant for an abbreviated new drug application certifies that it attempted in good faith to
			 create or negotiate entry into a single, shared system, but was unable to
			 finalize commercially reasonable terms with the holder of the listed drug
			 within 120 days, and such certification includes a description of the
			 efforts made by the applicant for the abbreviated new drug application to
			 create or negotiate entry into a single, shared system.</text>
            </clause>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection commented="no" id="H4FB5325E310C44C9860C50D395C48E6A">
        <enum>(d)</enum>
        <header>Effective date</header>
        <text display-inline="yes-display-inline">This section and the amendments made by this section shall take effect upon enactment, and shall
			 apply to all approved applications or licenses for a covered product (as
			 defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–2/ss:a" proposed="true">section 505–2(a) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>,
			 as added by this section) regardless of whether those applications or
			 licenses were approved before, on, or after the date of enactment of this
			 Act.</text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>